BergenBio Fundamentale Forhold (BGBIO)

vcp · januar 27, 2022, 6:20am

Ta gjerne en 40% oppgang i dag.
Vil ha mer info. Betydelig antall pas. Kunne spesielt tenkt meg mer info rundt sub protokoll. Antal pas. etc. drar på seg kostnader, men hvor mye?

TekBot · januar 27, 2022, 7:57pm

BerGenBio ASA: Increase of share capital, exercise of share options

Bergen, Norway, 27 January 2022

The Board of Directors in BerGenBio ASA (the"Company") (OSE: BGBIO) have, to
…

Vis børsmeldingen

fulfil the Company’s obligations under the share option agreements and in
accordance with the authorization granted by the general meeting on 19 March
2021, resolved to increase the Company’s share capital by NOK 10,000 by issuance
of 100,000 new shares. The new shares are subscribed for by option owners who
wishes and are entitled to exercise options in accordance with the Company’s
option scheme. Each option gives a right to receive one share in the Company.
The subscription price is in accordance with the prevailing options price
pursuant to the Company´s option scheme, in average NOK 15.33 per share.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,855,525.50 consisting of 88,555,255 shares, each with a par value of
NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

[email protected]

Rune Skeie

CFO, BerGenBio ASA

[email protected]

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Tekspert · februar 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@anon28800809 (1002 likes)

@Roc (191 likes)

[quote=“Roc, post:4209, topic:24374”]

@vcp (138 likes)

Resten av topp 10:

@Hayen (132 likes)
@Direkte (83 likes)
@Matadoren (77 likes)
@Scrivener (64 likes)
@Realize_1 (63 likes)
@Ekornet (55 likes)
@PankPinter (55 likes)

Gratulerer!

drdr · februar 1, 2022, 10:57pm

Utrolig kult at Bem. blir brukt som første/standard valg som AXL hemmer av forskjellige uavngige forskere og akademikere, og viser potensialet for å bli en blockbuster! Dette er en viktig element når BP skal vurdere en potensiel kandidat for M&A.

TekBot · februar 3, 2022, 1:09pm

BerGenBio ASA: Share capital increase

Bergen, Norway, 3 February 2022 - Reference is made to the stock exchange notice
published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 27 January 2022 where
the Company announced that the board of directors of the Company had resolved to
…

Vis børsmeldingen

increase the Company’s share capital in connection with the exercise of options
pursuant to the Company’s share option program. A total of 100,000 options were
exercised and 100,000 new shares were issued at an average subscription price of
NOK 15.33 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company’s share capital
is NOK 8,855,525.50 divided into 88,555,255 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

[email protected]

Rune Skeie

CFO, BerGenBio ASA

[email protected]

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and
other important factors. Such risks, uncertainties, contingencies and other
important factors could cause actual events to differ materially from the
expectations expressed or implied in this announcement by such forward-looking
statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

fuzzy · februar 5, 2022, 9:02pm

Har benyttet meg av https://www.reddit.com/r/Scholar/ noen ganger for å få tak i full tekst av artikler bak paywall.

Bare som et tips.

TekBot · februar 8, 2022, 6:00am

BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2021 RESULTS WEBCAST

Bergen, Norway,8 February 2022?-BerGenBioASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need,will be announcing its results for thefourthquarter
…

Vis børsmeldingen

2021 onWednesday 16 February 2022.

A briefing by BerGenBio’s senior management team will take place at 10:00 am CET
via a webcast presentation, followed by a Q&A session.

The live webcast link will be available at www.bergenbio.comin the
Investors/Financial Reports section. A recording will be available shortly after
the webcast has finished.

Thefourthquarter 2021 report and presentation will be available on the Company’s
website in the Investors/Financial Reports section from 7:00 am CET the same
day.

-Ends-

Contacts

Martin Olin
Chief Executive Officer, BerGenBio ASA
[email protected]

Rune Skeie
Chief FinancialOfficer, BerGenBio ASA
[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

ConsiliumStrategic Communications
[email protected]
+44 20 3709 5700

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing a
potential companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit? www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies, and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · februar 16, 2022, 6:01am

BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021

Bergen, Norway, 16 February 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, announces its results for the fourth quarter and
…

Vis børsmeldingen

full year 2021.

A briefing by BerGenBio’s senior management team will take place at 10:00am CET
today via a webcast presentation, followed by a Q&A session. Please see below
for details.

Operational Highlights - fourth quarter 2021 (including post-period end)

· Post-period end, BerGenBio announced its participation in the EU-SolidAct
trial, part of EU-RESPONSE, a pan-European research project involved with the
rapid and coordinated investigation of medications to treat COVID-19 during the
ongoing pandemic allowing BerGenBio to potentially confirm encouraging clinical
data at significantly reduced cost.
· Licensed key exclusive intellectual property rights from UT Southwestern
Medical Center, which strengthen the intellectual property estate for the
potential treatment of Non-Small Cell Cancer (NSCLC) patients with STK11
mutations.
· Granted Fast Track designation by the FDA for bemcentinib in combination
with an anti-PD-(L)1 agents as treatment for patients with STK11 altered
advanced/metastatic NSCLC patients without actionable mutations.
· Presented pre-clinical and clinical data on bemcentinib in STK11 mutated
NSCLC at SITC Annual Meeting 2021, indication that bemcentinib restores response
to anti-PD-1 treatments in NSCLC patients with STK11 mutations.
· Presented updated data from Phase II trial (BGBC003) of bemcentinib in
combination with low dose cytarabine (LDAC) in older, relapsed and refractory
AML patients at the 63rd Annual American Society of Hematology (ASH) Meeting.
· Anders Tullgren appointed as Chairman of the Board, bringing over 35 years
of global experience in both large pharmaceutical and small/mid-size biotech
environments.

Financial Highlights - fourth quarter and full year 2021

(Figures in brackets = same period 2020 unless otherwise stated)

· Revenue amounted toNOK 0.8 million (NOK 0.6 million) for the fourth quarter
and NOK 0.8 million (NOK 0.6 million) for the full year 2021
· Total operating expenses for the fourth quarter were NOK 68.1 million (NOK
72.4 million) and total operating expenses for the full year 2021 amounted to
315.2 million (NOK 261.7 million)
· The operating loss for the quarter came toNOK67.3million (NOK71.8million)
and NOK 314.5 million (NOK 261.1 million) for the full year 2021
· Cash and cash equivalents amounted to NOK 436.4 million at the end of
December 2021 (NOK 721.6 million by end of December 2020)

Martin Olin, Chief Executive Officer of BerGenBio, commented: "In the fourth
quarter of 2021 we continued to make significant progress in defining our
strategy and priorities to advance our two AXL development candidates. Our lead
development candidate, bemcentinib, a potentially first-in-class selective AXL
inhibitor currently undergoing Phase II clinical trials in NSCLC, AML and
respiratory infections (COVID-19), is well positioned for further advancement.

"Our strategy and priorities going forward will be anchored within a rigorous
data-driven framework, where the scientific rationale, pre-clinical and clinical
data define a compelling rationale for advancing our development candidates
towards potential treatment modalities addressing high unmet medical needs.

“With a clear strategy in place, I believe BerGenBio is well positioned to
progress and deliver on its potential. I look forward to providing you with
further updates on our progress.”

Presentation and Webcast Details

The live webcast link is available at www.bergenbio.com in the
Investors/Financial Reports section. A recording will be available shortly after
the webcast has finished.

Webcast link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20220216_7

Dial-in numbers:

NO: +47-21-956342

UK: +44-203-7696819

US: +1 646-787-0157

SE: +46-4-0682-0620

DK: +45 78768490

Pin: 712491

The fourth quarter and full year report and presentation will be made available
on the Company’s website in the Investors/Financial Reports section and a
recording of the webcast will be made available shortly after the webcast has
finished.

-Ends-

Contacts

Martin Olin
Chief Executive Officer, BerGenBio ASA
[email protected]

Rune Skeie
Chief FinancialOfficer, BerGenBio ASA
[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

ConsiliumStrategic Communications
[email protected]
+44 20 3709 5700

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing a
potential companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit? www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies, and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · februar 16, 2022, 4:11pm

BerGenBio ASA: Increase of share capital, exercise of share options

Bergen, Norway, 16 February 2022

The Board of Directors in BerGenBio ASA (the"Company") (OSE: BGBIO) have, to
…

Vis børsmeldingen

fulfil the Company’s obligations under the share option agreements and in
accordance with the authorization granted by the general meeting on 19 March
2021, resolved to increase the Company’s share capital by NOK 10,507.70 by
issuance of 105,277 new shares. The new shares are subscribed for by option
owners who wishes and are entitled to exercise options in accordance with the
Company’s option scheme. Each option gives a right to receive one share in the
Company. The subscription price is in accordance with the prevailing options
price pursuant to the Company´s option scheme, in average NOK 16.01 per share.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,866,053.20 consisting of 88,660,532, each with a par value of NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

[email protected]

Rune Skeie

CFO, BerGenBio ASA

[email protected]

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

vcp · februar 20, 2022, 7:19pm

Mulig jeg har sovet i timen, men denne var int. og kan være verd å dykke litt i.

« drug-induced expression of AXL

vcp · februar 21, 2022, 10:48am

Samme jeg fant i går, er en del studier som har funnet samme. Styrker muligheten for kombinasjon.

TekBot · februar 22, 2022, 11:01am

BerGenBio ASA: Share capital increase

Bergen, Norway, 22 February 2022 - Reference is made to the stock exchange
notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 16 February
2022 where the Company announced that the board of directors of the Company had
…

Vis børsmeldingen

resolved to increase the Company’s share capital in connection with the exercise
of options pursuant to the Company’s share option program. A total of 105,277
options were exercised and 105,277 new shares were issued at an average
subscription price of NOK 16.01 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company’s share capital
is NOK 8,866,053.20 divided into 88,660,532 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

[email protected]

Rune Skeie

CFO, BerGenBio ASA

[email protected]

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Tekspert · mars 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@anon28800809 (762 likes)

@vcp (160 likes)

@Direkte (104 likes)

Resten av topp 10:

@Matadoren (97 likes)
@PankPinter (69 likes)
@Hayen (65 likes)
@drdr (63 likes)
@Boms (54 likes)
@Roc (52 likes)
@Realize_1 (36 likes)

Gratulerer!

TekBot · mars 17, 2022, 7:00am

BERGENBIO TO PRESENT AT CARNEGIE VIRTUAL NORDIC HEALTHCARE SEMINAR

Bergen, Norway, 17 March 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, is pleased to announce that CEO Martin Olin will be
…

Vis børsmeldingen

presenting at the Carnegie Virtual Nordic Healthcare Seminar taking place today
at 15:15 CET.

The presentation will be made available on the Company’s website in the
Investors section shortly after the presentation.

-Ends-

Contacts

Martin Olin
Chief Executive Officer, BerGenBio ASA
[email protected]

Rune Skeie
Chief FinancialOfficer, BerGenBio ASA
[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

ConsiliumStrategic Communications
[email protected]
+44 20 3709 5700

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing a
potential companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit? www.bergenbio.com

Kilde

TekBot · mars 17, 2022, 7:16am

BERGENBIO ANNOUNCES PUBLICATION IN CELL REPORTS MEDICINE JOURNAL INDICATING EFFICACY OF BEMCENTINIB IN STK11/LKB1 LUNG CANCER POPULATION

The article identifies the key role of AXL inhibition in restoring response to
immune checkpoint blockade therapy in lung cancer with mutations in the
STK11/LKB1 gene
…

Vis børsmeldingen

Bergen, Norway - 17 March 2022- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, today announces the publication of a peer-reviewed article
entitled “AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant
NSCLC through expansion of TCF1+ CD8+ T cells” in the journalCell Reports
Medicine.

The article reports on research that identifies AXL as a critical targetable
driver of immune suppression in STK11/LKB1 mutated non-small cell lung cancer
(NSCLC). Mutations in STK11/LKB1 in NSCLC occur in approximately 20% of patients
and are associated with poor outcomes and limited response to immune checkpoint
blockade, commonly utilized treatments for lung cancer.

This article and its accompanying material are accessible here:

https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(22)00060
-X (Error during processing.
m%2Fcell-reports-medicine%2Ffulltext%2FS2666-3791(22)00060
-X&data=04%7C01%7Crune.skeie%40bergenbio.com%7Cb59bc32cca894be7b28c08da0745f8c4%7
C2b50b422ca6d42af9fc0741b248bb071%7C0%7C0%7C637830294373647052%7CUnknown%7CTWFpbG
Zsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&s
data=tLI4UnfigSyr29CNzY39A0Pfeugajy9AT6I%2Bu%2BXHUVI%3D&reserved=0)

The research was led by Professor Rolf A. Brekken, in the Hamon Center for
Therapeutic Oncology Research at the UT Southwestern Medical Center. The group
introduced a STK11/LKB1 mutation into a preclinical murine model of lung
adenocarcinoma, resulting in immune checkpoint blockade refractory tumors. The
group posits that the lack of response occurred because the STK11/LKB1 mutated
tumors lacked a specific population of immune cells (TCF1-expressing CD8+ immune
T cells). This immune cell population was also reduced in human NSCLC tumors
carrying STK11/LKB1 mutations.

Systemic inhibition of AXL by the BerGenBio molecule bemcentinib led to
increased type I interferon secretion from AXL-expressing dendritic cells,
resulting in expansion of the TCF1+ T cell population and restored therapeutic
response to immune checkpoint blockade treatment. These results were observed in
both an immunocompetent mouse model and in mice bearing human STK11/LKB1 mutant
NSCLC tumors along with a humanized immune system. The paper also summarizes
clinical data in NSCLC patients with identified STK11/LKB1 mutations receiving
bemcentinib and immune checkpoint blockage (pembrolizumab), who demonstrated
objective clinical response to combination therapy.

In November 2021 BerGenBio announced that the U.S. Food and Drug Administration
(FDA) granted Fast Track designation for bemcentinib in combination with an anti
-PD-(L)1 agent as a treatment for patients with STK11/LKB1 altered
advanced/metastatic NSCLC patients without actionable mutations.

Martin Olin, Chief Executive Officer of BerGenBio, commented: “We are pleased to
receive this strong preclinical validation of the potential role of bemcentinib
to treat STK11/LKB1 mutated NSCLC patients. Data suggests that this significant
patient population is underserved by current immune checkpoint blockade
therapies, and we hope that the combination with bemcentinib can restore the
immune response in these patients. The identification of a new druggable
biomarker segment such as the STK11/LKB1 mutations may offer significant hope
for improved patient outcomes in combination with the current standard of care
therapies. We look forward to initiating a clinical trial this year to advance
bemcentinib into development for this patient population.”

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA

[email protected]

Rune Skeie, CFO, BerGenBio ASA
[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Consilium Strategic
Communications
[email protected]
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

srh · mars 17, 2022, 7:37am

Noen som kan oversette dette til et menneskelig språk- i kortformat?

vcp · mars 17, 2022, 7:55am

Kort fortalt; Bra potensiale innenfor et gigantisk marked.

BgBio har allerede fått FDA Fast track her, etter respons i en NSCLC subgruppe.

Subgruppen utgjør ca; 20% av dette markedet:

Konventet den summen til nok

Fornybar · mars 17, 2022, 7:55am

Systemic inhibition of AXL by the BerGenBio molecule bemcentinib led to
increased type I interferon secretion from AXL-expressing dendritic cells,
resulting in expansion of the TCF1+ T cell population and restored therapeutic
response to immune checkpoint blockade treatment. These results were observed in
both an immunocompetent mouse model and in mice bearing human STK11/LKB1 mutant
NSCLC tumors along with a humanized immune system. The paper also summarizes
clinical data in NSCLC patients with identified STK11/LKB1 mutations receiving
bemcentinib and immune checkpoint blockage (pembrolizumab), who demonstrated
objective clinical response to combination therapy.

Når du gir BEM til en pasient øker utskillelse av Type 1 interferon (et stoff som er viktig for at immunforsvaret skal gi respons) fra dendritiske celler som uttrykker AXL. Dendritiske celler er en del av immunforsvaret, og disse ønsker du at skal være parat til å ta opp antigener og å lære opp T-celler til å angripe farlige ting. Det førte til en økning av T-celler og en gjenopprettet terapeutisk respons med sjekkpunkthemmere, dvs at immunforsvaret begynte å fungere igjen da de også gav sjekkpunkthemmere.

Disse forsøkene gjorde de i mus med friskt immunforsvar og i mus innsatt med STK11-mutert NSCLC (lungekreft) og innsatt menneskelig immunceller.

I tillegg har de sett på data fra pasienter i de andre lungekreftstudiene med bekreftet STK11-mutasjon.

BillyP · mars 17, 2022, 9:41am

Så et marked på NOK 70 milliarder på sikt. Hvs målgruppen utgjør 20% av tilfellene. Korrekt?

vcp · mars 17, 2022, 10:17am

Blir vel det, jeg ser det er litt varierende tall.
Om en er litt konservativ kan en si 50 milliarder, årlig

Får de gode nok resultater her, så står nok BP klar med en fin sum.

Men de køddene venter til moden data + så jeg forventer ikke avtale med det første.
Men et studie samarbeid er ikke helt utenkelig. De har en del av dem i pipen allerede.

Når jeg først er inne på det, hvor stor del av pipen er priset inn på det kursnivået en ser nå?
Enten vet noen, noe vi burde vist eller så er det ikke mye som er verdsatt.

Bare at familien Mohn er største eier er verd et par milliarder. Lol😄